Literature DB >> 7683158

Mechanisms of rabies virus neutralization.

A Flamand1, H Raux, Y Gaudin, R W Ruigrok.   

Abstract

The number of immunoglobulins necessary to neutralize rabies virus (CVS strain) was estimated using IgG and IgM monoclonal antibodies (MAb) specific to the three antigenic sites of the glycoprotein. It was estimated that below 130 IgG or 30 IgM bound per virions, infectivity was totally preserved. Neutralization occurred for an average of 1 or 2 IgG for 3 spikes and 1 IgM for 9 to 10 spikes on the virus surface. Saturation was obtained for 1 to 3 IgG per spike, depending on the antibody, and 1 IgM for 4 to 5 spikes. This result was confirmed by electron microscopy. Neutralization-resisting mutants which continued to fix the selecting MAb in ELISA were also investigated. In two cases, the lack of neutralization was due to the fact that the maximum number of immunoglobulins bound per virion was below the neutralizing dose. In one case, however, the mutant was able to fix the same number of IgG as the parental strain and was not neutralized, even at saturation. The capacity of the antibodies to reduce the attachment of the virus onto BSR cells was also examined. Every intermediate between no inhibition of the attachment and inhibition by a factor of 20 was found; even in this last case, inhibition of attachment was insufficient to explain the extent of neutralization. No correlation was found between the antigenic site recognized by the antibody and the level of inhibition. IgM inhibited attachment more than IgG and one IgG2b antibody did not inhibit attachment at all. The fusion of virions saturated with this antibody with artificial liposomes was totally inhibited, either specifically or because virus-antibody complexes did not attached to the liposomes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683158     DOI: 10.1006/viro.1993.1261

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  34 in total

1.  Functional interaction map of lyssavirus phosphoprotein: identification of the minimal transcription domains.

Authors:  Y Jacob; E Real; N Tordo
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

3.  Identification of amino acids controlling the low-pH-induced conformational change of rabies virus glycoprotein.

Authors:  Y Gaudin; H Raux; A Flamand; R W Ruigrok
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 4.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

5.  Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants.

Authors:  Alexander B H Bakker; Wilfred E Marissen; R Arjen Kramer; Amy B Rice; William C Weldon; Michael Niezgoda; Cathleen A Hanlon; Sandra Thijsse; Harold H J Backus; John de Kruif; Bernhard Dietzschold; Charles E Rupprecht; Jaap Goudsmit
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 6.  The glycoprotein G of rhabdoviruses.

Authors:  J M Coll
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

7.  Vesicular stomatitis virus M protein may be inside the ribonucleocapsid coil.

Authors:  A Barge; Y Gaudin; P Coulon; R W Ruigrok
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases.

Authors:  H W Virgin; M A Mann; K L Tyler
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

Review 9.  Rabies-specific antibodies: measuring surrogates of protection against a fatal disease.

Authors:  Susan M Moore; Cathleen A Hanlon
Journal:  PLoS Negl Trop Dis       Date:  2010-03-09

10.  Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles.

Authors:  T Mebatsion; M J Schnell; K K Conzelmann
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.